Trials / Sponsors / AIM ImmunoTech Inc.

AIM ImmunoTech Inc.

Industry · 9 registered clinical trials.

Status	Trial	Phase	Started
Suspended	Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC Pancreatic Cancer	Phase 2	2026-06-01
Completed	Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions Post COVID-19 Condition, Long COVID	Phase 2	2023-06-30
Terminated	Safety Study of FluMist With and Without Ampligen Influenza, Human	Phase 1 / Phase 2	2012-04-01
Terminated	A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects HIV Infections	Phase 2	2005-07-01
Completed	Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers Severe Acute Respiratory Syndrome	Phase 2	2004-11-01
Completed	The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART HIV Seropositivity, HIV Infection	Phase 2	2001-05-01
Terminated	Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART HIV Seropositivity, HIV Infection	Phase 2	2001-05-01
Completed	The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome Chronic Fatigue Syndrome, Myalgic Encephalomyelitis	Phase 3	1998-12-01
Temporarily Not Available	Ampligen in Chronic Fatigue Syndrome Chronic Fatigue Syndrome	—	—